Anti-sense Oligonucleotides – Innovation Insights, Competitive Analysis, Patents, Drugs, Clinical Trials and Deals

Anti-Sense Oligonucleotides Market Report Overview

Antisense oligonucleotides (ASO) are a class of biological medicine employed to alter the expression of mRNA and genes using various mechanisms to deliver therapeutic effects. Based on the patent bibliographic metrics, technology foresight identifies ASOs as high-impact innovations in the near term. Asia and North America have the highest drug development activity in anti-sense oligonucleotides. Furthermore, it is an accelerating innovation among 80+ innovations in the pharma industry according to the innovation s-curve framework.

Innovation S-Curve – Innovation Areas

Buy the Full Report for More Anti-Sense Oligonucleotides Innovation Insights, Download a Free Report Sample

Anti-sense oligonucleotides innovation insights market research report provides insights into antisense oligonucleotides tech activities, including informed R&D, strategic planning, competitive edge, market potential, and technology initiatives.

Anti-Sense Oligonucleotides Technology Foresights

Antisense oligonucleotides represent a promising therapeutic approach in healthcare, particularly for genetic and degenerative diseases. The advancements in oligonucleotide technology have opened new avenues for treatment, leading to significant market potential. ASOs are being explored for a variety of conditions, including rare genetic disorders, cancer, and neurodegenerative diseases. They have shown efficacy in modulating disease-causing genes, which positions them as a new class of medicine. Furthermore, partnerships, such as that between UMass Chan and QurAlis, are focusing on developing ASOs for conditions like fragile X syndrome, enhancing the pipeline of potential therapies.

Buy the Full Report for More Anti-Sense Oligonucleotides Technology Foresights, Download a Free Report Sample

Anti-Sense Oligonucleotides Segmentation by Drug Types

In 2024, innovator drugs predominantly represented anti-sense oligonucleotides whereas innovator (NME) accounted for a minimal share. Furthermore, Ionis Pharma, Sarepta Therapeutics, and Secarna Therapeutics among others are the major key players in the innovator drugs type.

Anti-Sense Oligonucleotides Drug Type Analysis, 2024 (%)

Buy the Full Report for More Anti-Sense Oligonucleotides Drug Type Insights, Download a Free Report Sample

Anti-Sense Oligonucleotides Segmentation by Route of Administration

The key routes of administration of anti-sense oligonucleotides are intravenous, subcutaneous, intrathecal, topical, and inhalational among others. Intravenous is the prominent RoA followed for anti-sense oligonucleotides.

Anti-Sense Oligonucleotides RoA Analysis, 2024 (%)

Buy the Full Report for More Anti-Sense Oligonucleotides RoA Insights, Download a Free Report Sample

Anti-Sense Oligonucleotides Drugs – Competitive Landscape

The key sponsors of anti-sense oligonucleotide drugs are Ionis Pharmaceutical Inc, AstraZeneca Inc., Biogen Inc, Sarepta Therapeutics Inc., and GSK Plc among others. Ionis Pharma was the leading sponsor of anti-sense oligonucleotides drugs in 2024.

Anti-Sense Oligonucleotides Drug Sponsors, 2024 (%)

Buy the Full Report for More Anti-Sense Oligonucleotides Drug Sponsor Insights, Download a Free Report Sample

Segments Covered in the Report

Anti-Sense Oligonucleotides Drug Type Outlook (2024)

• Innovator
• Innovator (NME)

Anti-Sense Oligonucleotides RoA Outlook (2024)

• Intravenous
• Subcutaneous
• Intrathecal
• Topical
• Inhalational
• Intravitreal
• Oral
• Parenteral
• Ophthalmic
• Intralesional
• Nasal
• Intratumor
• Intraarticular

Scope

The report provides:

• Innovation Insights: innovation examples by each use case segment of various sectors to present key trends.
• Key player: This represents a sample list of key players in each use case highlighted in the report.
• Startups: This represents a sample list of emerging startups in each use case highlighted in the report.
• University: This represents a sample list of leading universities in each use case highlighted in the report.

Key Highlights

• Antisense oligonucleotides (ASO) are a high-impact innovation in the pharmaceutical industry, with the potential to alter gene expression and mRNA using various mechanisms for therapeutic purposes.
• The patent analysis indicates that ASO innovation is primarily driven by universities and public-listed pharmaceutical companies, with the United States being the leading geography in terms of activity. However, there is a growing trend of academy-industry collaborations driving innovation in ASOs.
• The ASO therapeutics landscape is concentrated among a limited number of companies, with Sarepta, Ionis, and Opko Health (Camp4) having the highest number of patents. Sarepta and Ionis also rank highly in terms of patent portfolio strength indicators. There is limited activity in China, with only one China-based company identified with patents in this area.
• Startups in the ASO field, such as Remix Therapeutics, Ractigen, and Secarna Pharma, are emerging as key players in innovation and development. While the majority of startups are based outside of China, there are three China-based startups identified in the ASO space.
• The drug landscape for ASOs is dominated by innovator drugs, with a strong focus on oncology and central nervous system (CNS) disorders. Major pharmaceutical companies like Ionis Pharma, Sarepta Therapeutic Inc, AstraZeneca, and Biogen Inc are leading the way in drug development, particularly in preclinical and phase II trials.

Reasons to Buy

• No surprise that technology has been a driving force in business transformation for years, but the term ‘emerging technologies’ has all of suddenly become the key catalyst to drive the next wave of innovation across sectors.
• Antisense oligonucleotides (ASOs) provide comprehensive insights into the latest advancements, market analysis, and competitive intelligence. It helps in strategic planning by offering detailed data on patents, drugs, clinical trials, and deals. The report keeps you updated on regulatory and clinical developments, crucial for navigating the healthcare landscape. Additionally, it identifies investment opportunities by analyzing financial deals and funding trends, ensuring you stay ahead in the field. This information is valuable for making informed business decisions and understanding the activities of top pharmaceutical companies, startups, and universities.